Swiss pharmaceutical and nutritional ingredients player Lonza beat 2017 earnings expectations, but forecast a rise in operating profit margin this year that fell short of analysts’ hopes, knocking its shares.
Yesterday’s article Carnitine transporter may adapt to lower levels in vegetarians: Study incorrectly stated that Lonza’s L-Carnitine ingredient Carnipure is derived from animal sources. In fact, it is vegetarian.
Lonza is building the technological basis of its nutrition business
with the acquisition of assets from Canada's SAM Electron
Technologies, plus the license for innovative and ecological
vitamin K production technology.
Swiss fine chemicals group Lonza said yesterday that it saw strong
demand for its nutrition products during the first half but high
raw material and energy costs continued to erode margins, writes
Lonza and Nutraceutical Corporation have reached a settlement in
their L-Carnitine patent dispute, obliging Nutraceutical to source
all its L-Carnitine L-Tartrine in the US from Lonza, writes Jess
Swiss chemicals firm Lonza has carried out a new study which
confirms that supplementation with L-Carnitine can significantly
increase fatty acid oxidation in healthy adults in a short period
of time without causing loss of muscle...
Swiss intermediates and fine chemical company Lonza said today it
is to cut around 500 jobs mainly in Europe and the US as part of a
restructuring programme to reduce the negative effects of the
current economy on most of its business...
The Lonza Group announced the settlement on Friday of their
recently filed Carnitine patent infringement actions against
Barrington Chemical Corporation, Carnitech and Nutritional Sourcing
Swiss chemicals company the Lonza Group said today it topped the
previous year's performance, with operating income, excluding
non-recurring items, up from CHF413 million to CHF419 million
(€286.5m). The group confirmed its targets...
Lonza Ltd and Lonza Inc, both subsidiaries of Swiss chemicals
company Lonza Group, have filed a series of patent infringement
lawsuits against supplement companies Carnitech, Barrington,
Stauber and Axel Chemical in the US.
Swiss fine chemicals company Lonza said today that Martin Ebner's
BZ Group Holding plans to sell its 19.8 per cent stake in the
business in the coming weeks in a bid to raise cash for the
Lonza, the Swiss-based pharmaceuticals company, has said that the
US Food and Drug Administration has allowed the sale of PepZin GI,
the subject of a new dietary ingredient submission to the federal
Switzerland's Lonza group has confirmed its commitment to the
construction of a major new production facility in the town of Visp
with the announcement of a SFr100 million (€68.4m) investment in a